AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials — LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma — along with completion of LP-184 Phase 1a enrollment, positioning it for Phase 1b/2 studies in high-value indications. LP-184 has FDA Fast Track and multiple Rare Pediatric Disease designations and showed significant survival gains in ATRT models. Lantern strengthened its IP with a European patent allowance for LP-284 and publication of…